These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 19162147)

  • 1. Production and characterization of Hesperetin nanosuspensions for dermal delivery.
    Mishra PR; Al Shaal L; Müller RH; Keck CM
    Int J Pharm; 2009 Apr; 371(1-2):182-9. PubMed ID: 19162147
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Resveratrol nanosuspensions for dermal application--production, characterization, and physical stability.
    Kobierski S; Ofori-Kwakye K; Müller RH; Keck CM
    Pharmazie; 2009 Nov; 64(11):741-7. PubMed ID: 20099519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preserving hesperetin nanosuspensions for dermal application.
    Al Shaal L; Müller RH; Keck CM
    Pharmazie; 2010 Feb; 65(2):86-92. PubMed ID: 20225649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol nanosuspensions: interaction of preservatives with nanocrystal production.
    Kobierski S; Ofori-Kwakye K; Müller RH; Keck CM
    Pharmazie; 2011 Dec; 66(12):942-7. PubMed ID: 22312699
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of ascorbyl palmitate nanocrystals applying the nanosuspension technology.
    Teeranachaideekul V; Junyaprasert VB; Souto EB; Müller RH
    Int J Pharm; 2008 Apr; 354(1-2):227-34. PubMed ID: 18242898
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Nanosuspensions: a promising formulation for the new phospholipase A2 inhibitor PX-18.
    Pardeike J; Müller RH
    Int J Pharm; 2010 May; 391(1-2):322-9. PubMed ID: 20214969
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nanosuspensions of hesperetin: preparation and characterization.
    Al Shaal L; Mishra PR; Müller RH; Keck CM
    Pharmazie; 2014 Mar; 69(3):173-82. PubMed ID: 24716405
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Polyhydroxy surfactants for the formulation of lipid nanoparticles (SLN and NLC): effects on size, physical stability and particle matrix structure.
    Kovacevic A; Savic S; Vuleta G; Müller RH; Keck CM
    Int J Pharm; 2011 Mar; 406(1-2):163-72. PubMed ID: 21219990
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Industrial concentrates of dermal hesperidin smartCrystals®--production, characterization & long-term stability.
    Romero GB; Chen R; Keck CM; Müller RH
    Int J Pharm; 2015 Mar; 482(1-2):54-60. PubMed ID: 25448556
    [TBL] [Abstract][Full Text] [Related]  

  • 10. smartCrystal combination technology--scale up from lab to pilot scale and long term stability.
    Al Shaal L; Müller RH; Shegokar R
    Pharmazie; 2010 Dec; 65(12):877-84. PubMed ID: 21284256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stability of lipid excipients in solid lipid nanoparticles.
    Radomska-Soukharev A
    Adv Drug Deliv Rev; 2007 Jul; 59(6):411-8. PubMed ID: 17553589
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lutein nanocrystals as antioxidant formulation for oral and dermal delivery.
    Mitri K; Shegokar R; Gohla S; Anselmi C; Müller RH
    Int J Pharm; 2011 Nov; 420(1):141-6. PubMed ID: 21884768
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanosuspensions of poorly soluble drugs: preparation and development by wet milling.
    Liu P; Rong X; Laru J; van Veen B; Kiesvaara J; Hirvonen J; Laaksonen T; Peltonen L
    Int J Pharm; 2011 Jun; 411(1-2):215-22. PubMed ID: 21458552
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nanostructured lipid carriers (NLC) on the basis of Siberian pine (Pinus sibirica) seed oil.
    Averina ES; Seewald G; Müller RH; Radnaeva LD; Popov DV
    Pharmazie; 2010 Jan; 65(1):25-31. PubMed ID: 20187575
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The effect of critical process parameters of the high pressure homogenization technique on the critical quality attributes of flurbiprofen nanosuspensions.
    Oktay AN; Ilbasmis-Tamer S; Celebi N
    Pharm Dev Technol; 2019 Dec; 24(10):1278-1286. PubMed ID: 31535942
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Encapsulation of ascorbyl palmitate in nanostructured lipid carriers (NLC)--effects of formulation parameters on physicochemical stability.
    Teeranachaideekul V; Müller RH; Junyaprasert VB
    Int J Pharm; 2007 Aug; 340(1-2):198-206. PubMed ID: 17482778
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cationic solid lipid nanoparticles (cSLN): structure, stability and DNA binding capacity correlation studies.
    Doktorovova S; Shegokar R; Rakovsky E; Gonzalez-Mira E; Lopes CM; Silva AM; Martins-Lopes P; Muller RH; Souto EB
    Int J Pharm; 2011 Nov; 420(2):341-9. PubMed ID: 21907778
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Studies on pharmacokinetics and tissue distribution of oridonin nanosuspensions.
    Gao L; Zhang D; Chen M; Duan C; Dai W; Jia L; Zhao W
    Int J Pharm; 2008 May; 355(1-2):321-7. PubMed ID: 18242896
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) -- structural investigations on two different carrier systems.
    Saupe A; Wissing SA; Lenk A; Schmidt C; Müller RH
    Biomed Mater Eng; 2005; 15(5):393-402. PubMed ID: 16179760
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Freeze-dried nifedipine-lipid nanoparticles with long-term nano-dispersion stability after reconstitution.
    Ohshima H; Miyagishima A; Kurita T; Makino Y; Iwao Y; Sonobe T; Itai S
    Int J Pharm; 2009 Jul; 377(1-2):180-4. PubMed ID: 19446623
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.